D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.
Identifieur interne : 001860 ( PubMed/Corpus ); précédent : 001859; suivant : 001861D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.
Auteurs : L. Pierot ; C. Desnos ; J. Blin ; R. Raisman ; D. Scherman ; F. Javoy-Agid ; M. Ruberg ; Y. AgidSource :
- Journal of the neurological sciences [ 0022-510X ] ; 1988.
English descriptors
- KwdEn :
- Adenylyl Cyclases (metabolism), Adult, Aged, Benzazepines (metabolism), Caudate Nucleus (metabolism), Dopamine Antagonists, Humans, Middle Aged, Parkinson Disease (metabolism), Putamen (metabolism), Receptors, Dopamine (metabolism), Receptors, Dopamine D1, Receptors, Dopamine D2, Reference Values, Spiperone (metabolism), Supranuclear Palsy, Progressive (metabolism), Tetrabenazine (analogs & derivatives), Tetrabenazine (metabolism).
- MESH :
- chemical , analogs & derivatives : Tetrabenazine.
- chemical , metabolism : Adenylyl Cyclases, Benzazepines, Receptors, Dopamine, Spiperone, Tetrabenazine.
- metabolism : Caudate Nucleus, Parkinson Disease, Putamen, Supranuclear Palsy, Progressive.
- Adult, Aged, Dopamine Antagonists, Humans, Middle Aged, Receptors, Dopamine D1, Receptors, Dopamine D2, Reference Values.
Abstract
The densities of D1- and D2-type dopamine receptors were measured with [3H]SCH23390 and [3H]spiperone, in the caudate nucleus and putamen of a large series of patients with Parkinson's disease or progressive supranuclear palsy, in relation to markers of dopaminergic and cholinergic innervation of the striatum ([3H]dihydrotetrabenazine binding and choline acetyltransferase activity). Correlations were sought between these parameters and clinical characteristics of the patients (abnormal involuntary movements, dementia, confusional syndrome or treatment). In Parkinson's disease, the densities of both types of receptors were unchanged, whereas in PSP, the density of D2, but not D1-type dopamine receptors, was decreased in the caudate nucleus and the putamen. No correlations between the biochemical and clinical data were found.
PubMed: 2975699
Links to Exploration step
pubmed:2975699Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.</title><author><name sortKey="Pierot, L" sort="Pierot, L" uniqKey="Pierot L" first="L" last="Pierot">L. Pierot</name><affiliation><nlm:affiliation>INSERM U. 289, Hôpital de la Salpêtrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Desnos, C" sort="Desnos, C" uniqKey="Desnos C" first="C" last="Desnos">C. Desnos</name></author><author><name sortKey="Blin, J" sort="Blin, J" uniqKey="Blin J" first="J" last="Blin">J. Blin</name></author><author><name sortKey="Raisman, R" sort="Raisman, R" uniqKey="Raisman R" first="R" last="Raisman">R. Raisman</name></author><author><name sortKey="Scherman, D" sort="Scherman, D" uniqKey="Scherman D" first="D" last="Scherman">D. Scherman</name></author><author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F" last="Javoy-Agid">F. Javoy-Agid</name></author><author><name sortKey="Ruberg, M" sort="Ruberg, M" uniqKey="Ruberg M" first="M" last="Ruberg">M. Ruberg</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1988">1988</date><idno type="RBID">pubmed:2975699</idno><idno type="pmid">2975699</idno><idno type="wicri:Area/PubMed/Corpus">001860</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001860</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.</title><author><name sortKey="Pierot, L" sort="Pierot, L" uniqKey="Pierot L" first="L" last="Pierot">L. Pierot</name><affiliation><nlm:affiliation>INSERM U. 289, Hôpital de la Salpêtrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Desnos, C" sort="Desnos, C" uniqKey="Desnos C" first="C" last="Desnos">C. Desnos</name></author><author><name sortKey="Blin, J" sort="Blin, J" uniqKey="Blin J" first="J" last="Blin">J. Blin</name></author><author><name sortKey="Raisman, R" sort="Raisman, R" uniqKey="Raisman R" first="R" last="Raisman">R. Raisman</name></author><author><name sortKey="Scherman, D" sort="Scherman, D" uniqKey="Scherman D" first="D" last="Scherman">D. Scherman</name></author><author><name sortKey="Javoy Agid, F" sort="Javoy Agid, F" uniqKey="Javoy Agid F" first="F" last="Javoy-Agid">F. Javoy-Agid</name></author><author><name sortKey="Ruberg, M" sort="Ruberg, M" uniqKey="Ruberg M" first="M" last="Ruberg">M. Ruberg</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y" last="Agid">Y. Agid</name></author></analytic><series><title level="j">Journal of the neurological sciences</title><idno type="ISSN">0022-510X</idno><imprint><date when="1988" type="published">1988</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenylyl Cyclases (metabolism)</term><term>Adult</term><term>Aged</term><term>Benzazepines (metabolism)</term><term>Caudate Nucleus (metabolism)</term><term>Dopamine Antagonists</term><term>Humans</term><term>Middle Aged</term><term>Parkinson Disease (metabolism)</term><term>Putamen (metabolism)</term><term>Receptors, Dopamine (metabolism)</term><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term><term>Reference Values</term><term>Spiperone (metabolism)</term><term>Supranuclear Palsy, Progressive (metabolism)</term><term>Tetrabenazine (analogs & derivatives)</term><term>Tetrabenazine (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Tetrabenazine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adenylyl Cyclases</term><term>Benzazepines</term><term>Receptors, Dopamine</term><term>Spiperone</term><term>Tetrabenazine</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Caudate Nucleus</term><term>Parkinson Disease</term><term>Putamen</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dopamine Antagonists</term><term>Humans</term><term>Middle Aged</term><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term><term>Reference Values</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The densities of D1- and D2-type dopamine receptors were measured with [3H]SCH23390 and [3H]spiperone, in the caudate nucleus and putamen of a large series of patients with Parkinson's disease or progressive supranuclear palsy, in relation to markers of dopaminergic and cholinergic innervation of the striatum ([3H]dihydrotetrabenazine binding and choline acetyltransferase activity). Correlations were sought between these parameters and clinical characteristics of the patients (abnormal involuntary movements, dementia, confusional syndrome or treatment). In Parkinson's disease, the densities of both types of receptors were unchanged, whereas in PSP, the density of D2, but not D1-type dopamine receptors, was decreased in the caudate nucleus and the putamen. No correlations between the biochemical and clinical data were found.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2975699</PMID><DateCreated><Year>1989</Year><Month>03</Month><Day>22</Day></DateCreated><DateCompleted><Year>1989</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-510X</ISSN><JournalIssue CitedMedium="Print"><Volume>86</Volume><Issue>2-3</Issue><PubDate><Year>1988</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of the neurological sciences</Title><ISOAbbreviation>J. Neurol. Sci.</ISOAbbreviation></Journal><ArticleTitle>D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.</ArticleTitle><Pagination><MedlinePgn>291-306</MedlinePgn></Pagination><Abstract><AbstractText>The densities of D1- and D2-type dopamine receptors were measured with [3H]SCH23390 and [3H]spiperone, in the caudate nucleus and putamen of a large series of patients with Parkinson's disease or progressive supranuclear palsy, in relation to markers of dopaminergic and cholinergic innervation of the striatum ([3H]dihydrotetrabenazine binding and choline acetyltransferase activity). Correlations were sought between these parameters and clinical characteristics of the patients (abnormal involuntary movements, dementia, confusional syndrome or treatment). In Parkinson's disease, the densities of both types of receptors were unchanged, whereas in PSP, the density of D2, but not D1-type dopamine receptors, was decreased in the caudate nucleus and the putamen. No correlations between the biochemical and clinical data were found.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pierot</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>INSERM U. 289, Hôpital de la Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desnos</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Blin</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Raisman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Scherman</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Javoy-Agid</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ruberg</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Agid</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neurol Sci</MedlineTA><NlmUniqueID>0375403</NlmUniqueID><ISSNLinking>0022-510X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001552">Benzazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>3466-75-9</RegistryNumber><NameOfSubstance UI="C032811">dihydrotetrabenazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>4X6E73CJ0Q</RegistryNumber><NameOfSubstance UI="D013134">Spiperone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.6.1.1</RegistryNumber><NameOfSubstance UI="D000262">Adenylyl Cyclases</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z9O08YRN8O</RegistryNumber><NameOfSubstance UI="D013747">Tetrabenazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000262" MajorTopicYN="N">Adenylyl Cyclases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001552" MajorTopicYN="N">Benzazepines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002421" MajorTopicYN="N">Caudate Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018492" MajorTopicYN="N">Dopamine Antagonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011699" MajorTopicYN="N">Putamen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013134" MajorTopicYN="N">Spiperone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013747" MajorTopicYN="N">Tetrabenazine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2975699</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001860 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001860 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:2975699
|texte= D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:2975699" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |